Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery

• Published in: Nanoscale 2018-12, Vol.11 (1), p.219-236
• Main Authors: Sims, Kenneth R, Liu, Yuan, Hwang, Geelsu, Jung, Hoi In, Koo, Hyun, Benoit, Danielle S. W
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - chemistry; Antiinfectives and antibacterials; Biofilms; Biomass; Cations; Cell Membrane - metabolism; Cell membranes; Disruption; Drug Carriers; Drug Delivery Systems; Drug Design; Durapatite - chemistry; Farnesol - chemistry; Formulations; Glucan; Glucans - chemistry; Hydrogen-Ion Concentration; Hydroxyapatite; Micelles; Microorganisms; Microscopy, Confocal; Molecular weight; Nanoparticles; Nanoparticles - chemistry; Polymers - chemistry; Pyrimidines - chemistry; Quaternary Ammonium Compounds - chemistry; Saliva; Streptococcus mutans - metabolism
• ISSN: 2040-3364; 2040-3372
• DOI: 10.1039/c8nr05784b

Biofilms are surface-bound, structured microbial communities underpinning persistent bacterial infections. Biofilms often create acidic pH microenvironments, providing opportunities to leverage responsive drug delivery systems to improve antibacterial efficacy. Here, the antibacterial efficacy of novel formulations containing pH-responsive polymer nanoparticle carriers (NPCs) and farnesol, a hydrophobic antibacterial drug, were investigated. Multiple farnesol-loaded NPCs, which varied in overall molecular weight and corona-to-core molecular weight ratios (CCRs), were tested using standard and saturated drug loading conditions. NPCs loaded at saturated conditions exhibited ∼300% greater drug loading capacity over standard conditions. Furthermore, saturated loading conditions sustained zero-ordered drug release over 48 hours, which was 3-fold longer than using standard farnesol loading. Anti-biofilm activity of saturated NPC loading was markedly amplified using Streptococcus mutans as a biofilm-forming model organism. Specifically, reductions of ∼2-4 log colony forming unit (CFU) were obtained using microplate and saliva-coated hydroxyapatite biofilm assays. Mechanistically, the new formulation reduced total biomass by disrupting insoluble glucan formation and increased NPC-cell membrane localization. Finally, thonzonium bromide, a highly potent, FDA-approved antibacterial drug with similar alkyl chain structure to farnesol, was also loaded into NPCs and used to treat S. mutans biofilms. Similar to farnesol-loaded NPCs, thonzonium bromide-loaded NPCs increased drug loading capacity ≥2.5-fold, demonstrated nearly zero-order release kinetics over 96 hours, and reduced biofilm cell viability by ∼6 log CFU. This work provides foundational insights that may lead to clinical translation of novel topical biofilm-targeting therapies, such as those for oral diseases. Novel polymer nanoparticle formulation improved drug loading, demonstrated zero-order release, and amplified anti-biofilm activity via increased bacterial membrane localization.